SEC 13F Intelligence

Lion Point Capital, LP / SNDX

Lion Point Capital, LP’s Syndax Pharmaceuticals Inc Position

Does Lion Point Capital, LP own Syndax Pharmaceuticals Inc (SNDX)? Yes36.0K shares worth $840,960 (+5.03% of its 13F portfolio) as of Q1 2026.

Position Value
$840,960
Q1 2026
Shares
36.0K
% of Portfolio
+5.03%
Quarters Held
12
currently held

Position History SNDX

Reported value by quarter
Q2 ’23: $722,085Q2 ’23Q3 ’23: $500,940Q4 ’23: $745,545Q4 ’23Q1 ’24: $2MQ2 ’24: $1MQ2 ’24Q3 ’24: $889,350Q4 ’24: $727,100Q4 ’24Q1 ’25: $675,675Q2 ’25: $515,075Q2 ’25Q3 ’25: $846,175Q4 ’25: $756,360Q4 ’25Q1 ’26: $840,960filingsflow.com
QuarterSharesValue% of Portfolio
Q1 202636.0K$840,960+5.03%
Q4 202536.0K$756,360+3.91%
Q3 202555.0K$846,175+4.81%
Q2 202555.0K$515,075+3.50%
Q1 202555.0K$675,675+4.31%
Q4 202455.0K$727,100+3.81%
Q3 202446.2K$889,350+1.98%
Q2 202465.0K$1M+2.43%
Q1 202465.0K$2M+0.86%
Q4 202334.5K$745,545+0.37%
Q3 202334.5K$500,940+0.22%
Q2 202334.5K$722,085+0.33%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Lion Point Capital, LP’s full portfolio or all institutional holders of SNDX.